“The present quality of care to estimate disease recurrence is CT imaging, which might just detect recurrence following important organ damage has happened,” explained Razelle Kurzrock, M.D., Center for Personalized Cancer Therapy and Clinical Trials Office manager, Moores Cancer in UC San Diego Health. “Discovering disease recurrence in these patients using a blood sample can enable more rapid and detailed treatment choices .”

When surgeons run on cancer sufferers, it’s with an objective to eliminate as much of their malignancy as you can and to accomplish a macroscopically-complete resection, which describes the elimination of all visible tumor cells. But, it’s the microscopic cells that could be left that may flourish and spread, resulting in recurrence.

Mesothelioma, an odd type of cancer brought on by exposure to airborne asbestos fibers, frequently includes an intricate development pattern making whole surgical removal an extremely tough endeavor. The use of a simple blood test that may predict a mesothelioma patient’s possibility of recurrence and response to therapies may mean elongated survival.

“We think that clinical outcomes from our patented technology can provide doctors with important information to predict a patient’s response to treatment and track their disease advancement and recurrence, which may result in better patient outcomes,” explained Biocept’s President and Chief Executive Officer Michael Nall.

Though mesothelioma and lung cancer are different cancers, the treatment protocol is comparable. The outcomes of the studies will likely be followed carefully. Roughly 3,000 Americans are diagnosed annually with all terminal cancer.